$BMRN News

BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky

BioMarin Reveals Dwarfism Study Data, Stock Soars

BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint

BioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 Deficiency

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

BMRN Stock Down on Mixed Results From Rare Disease Therapy Study

B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth

BioMarin drug acquired in buyout misses goal in rare disease study

Citigroup Initiates Coverage On BioMarin Pharmaceutical with Buy Rating, Announces Price Target of $75

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $50

BioMarin Pharmaceutical Announces Results From Phase 3 Study Of BMN 401 In Children Ages 1-12 With ENPP1 Deficiency; Study Meets Only One Co-Primary Endpoint, Shows No Improvement In Tracked Treatment Impact Scores

2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down

A Look At BioMarin Pharmaceutical (BMRN) Valuation As Guidance Rises And New VOXZOGO Data Emerges

BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Evercore ISI Lifts PT on BioMarin Pharmaceutical Inc. (BMRN)